EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors

Blair McNamara iD, Michelle Greenman iD, Nicole Pebley iD, Levent Mutlu iD, Alessandro D Santin iD

Molecules · 02.11.2023 · 28 (21) · 7389

DOI: 10.3390/molecules28217389 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 02.11.2023. Verfasst von Blair McNamara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA. Hauptthemen laut MEDLINE: Immunoconjugates, Genital Neoplasms, Female, Antineoplastic Agents. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, NIH Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugates (ADCs) are a new class of targeted anti-cancer therapies that combine a monoclonal tumor-surface-receptor-targeting antibody with a highly cytotoxic molecule payload bonded through specifically designed cleavable or non-cleavable chemical linkers. One such tumor surface receptor is human epidermal growth factor 2 (HER2), which is of interest for the treatment of many gynecologic tumors. ADCs enable the targeted delivery of a variety of cytotoxic therapies to tumor cells while minimizing delivery to healthy tissues. This review summarizes the existing literature about HER2-targeting ADC therapies approved for use in gynecologic malignancies, relevant preclinical studies, strategies to address ADC resistance, and ongoing clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesGenital Neoplasms, FemaleAntineoplastic AgentsFemaleHumansAntibodies, MonoclonalEpidermal Growth FactorErb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

ERBB2HER2antibody–drug conjugatecervical cancerchemotherapyendometrial cancergynecologic malignancyovarian cancer

Substanzen

ImmunoconjugatesAntineoplastic AgentsAntibodies, MonoclonalEpidermal Growth FactorErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.

ORCID-Profile: Blair McNamara, Michelle Greenman, Nicole Pebley, Levent Mutlu, Alessandro D Santin

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • NIH Research
  • Standup-to-Cancer (SU2C) Convergence
  • Deborah Bunn Alley Foundation
  • Domenic Cicchetti Foundation
  • Discovery to Cure Foundation
  • Guido Berlucchi Foundation

Zitieren

APA

McNamara, B., Greenman, M., Pebley, N., Mutlu, L., & Santin, A. D. (2023). Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors. Molecules, 28(21), 7389. https://doi.org/10.3390/molecules28217389

Vancouver

McNamara B, Greenman M, Pebley N, Mutlu L, Santin AD. Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors. Molecules. 2023;28(21):7389. doi:10.3390/molecules28217389

BibTeX
@article{McNamara2023,
  author = {McNamara, Blair and Greenman, Michelle and Pebley, Nicole and Mutlu, Levent and Santin, Alessandro D},
  title = {Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {21},
  pages = {7389},
  doi = {10.3390/molecules28217389}
}
Kostenlos starten →